Bienen- und Wespengiftallergien bei Hunden – Von der Akutbehandlung bis zur Desensibilisierung

Rostaher, Ana

doi:10.1055/a-0672-5658

Cited by 3 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retrospectively evaluating the case, we would like to emphasize that when our patient was presented with anaphylactic shock to the emergency veterinarian, further diagnostic evaluations (especially blood pressure and pulse oximetry) should have been performed, with possible subsequent iv administration of epinephrine 1,12 . It should be noted that epinephrine is considered as the treatment of choice for emergencies of anaphylaxis acting both as a vasopressor (improving blood pressure and organ perfusion), and bronchodilator, decreasing the production of inflammation mediators 1,12 . Most importantly, it cannot be replaced with antihistamines or glucocorticoids 1,12 .…”

Section: Discussionmentioning

confidence: 99%

“… 1–3 . Venomous insect hypersensitivity is a Type‐I reaction, however, its prevalence in animals remains unknown 1,2,4 . Typical localized symptoms may include, pain and swelling or a large localised reaction (diameter extending 10 cm) 1,2,4 .…”

Section: Introductionmentioning

confidence: 99%

“…Additionally to the hypersensitivity reactions, intoxications (dose‐dependent) can also occur after massive envenomation. Signs such as rhabdomyolysis, haemolysis, kidney and liver injury, even cerebral damage, and death (estimated lethal doses 20 stings/kg) have been previously described 1,2 . Depending on the signs and their severity, different treatment options are recommended 1,2 .…”

Section: Introductionmentioning

confidence: 99%

“…Signs such as rhabdomyolysis, haemolysis, kidney and liver injury, even cerebral damage, and death (estimated lethal doses 20 stings/kg) have been previously described 1,2 . Depending on the signs and their severity, different treatment options are recommended 1,2 . Briefly, antihistamines, glucocorticoids, epinephrine, and even hospitalization with intravenous (iv) fluids are treatment options 2,5 .…”

Section: Introductionmentioning

confidence: 99%

“…Briefly, antihistamines, glucocorticoids, epinephrine, and even hospitalization with intravenous (iv) fluids are treatment options 2,5 . If severe, systemic signs (e.g., anaphylactic shock) occur, then venom immunotherapy (VIT) should be considered 1,2 . Although in human medicine data show that VIT has a good efficacy (77–84% for bees and up to 96% for wasps), 5 no data exist in veterinary medicine 1,2,5 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

Apostolopoulos

Mayer

2021

Vet Record Case Reports

View full text Add to dashboard Cite

A four‐month‐old female Beagle, with a history of repeated anaphylactic reactions, was managed with venom immunotherapy (VIT), based on the results of a blood allergy test. Because there is a lack of VIT for dogs, a product from human medicine was used, which requires human serum albumin (HSA) in the solvent as a stabilizer. HSA has been described to cause sensitization and anaphylactic reactions, as well as other adverse effects in dogs. To avoid such adverse effects, water for injection was used as a solvent. VIT was initiated with a one‐day ultra‐rush induction scheme, followed by a conventional protocol as maintenance. The dog was stung by a bee after 11 months of VIT, presenting only mild lip edema. VIT is performed for the last 35 months. To the authors’ knowledge, this is the first report of a successful VIT using water for injection as a solvent, without HSA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

Apostolopoulos

Mayer

2021

Vet Record Case Reports

View full text Add to dashboard Cite

show abstract

Hymenoptera Venom Immunotherapy in DOGS: Safety and Clinical Efficacy

Rostaher,

Fischer,

Vigani

et al. 2023

Preprint

View full text Add to dashboard Cite

Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 g of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phase. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.

show abstract

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Rostaher,

Fischer,

Vigani

et al. 2023

Animals

View full text Add to dashboard Cite

Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.

show abstract

Bienen- und Wespengiftallergien bei Hunden – Von der Akutbehandlung bis zur Desensibilisierung

Cited by 3 publications

References 15 publications

Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

Hymenoptera Venom Immunotherapy in DOGS: Safety and Clinical Efficacy

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Contact Info

Product

Resources

About